Lilly announces phase 3 monarchE trial of Verzenio increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy: Indianapolis Friday, August 2 ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term on LLY stock.

Eli Lilly and Company drives growth with innovative diabetes and obesity drugs, expanding portfolios, and R&D strength. Click for more on LLY stock prospects.

Right now, the only oral GLP-1 drug is Novo Nordisk’s Rybelsus, a pill form of semaglutide approved only for diabetes, not obesity. Novo is pursuing a higher-dose version aimed at weight loss, which ...

WEDNESDAY, Aug. 27, 2025 (HealthDay News) — Eli Lilly says its new once-daily pill, orforglipron, helped people lose ...

Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III ...

Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU ...

Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of ...

New drug reverses liver damage in MASH, targeting an enzyme to reduce fat and inflammation in patients with fatty liver ...

In a new study, artificial intelligence matched and potentially exceeded the performance of gastroenterologists and conventional scoring in evaluating endoscopies of Crohn’s disease patients.